Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Determinants of long-term survival in patients with IDH-mutant gliomas.

Journal of neuro-oncology - 1 Dec 2024

Katzendobler Sophie, Niedermeyer Sebastian, Blobner Jens, Trumm Christoph, Harter Patrick N, von Baumgarten Louisa, Stoecklein Veit M, Tonn Joerg-Christian, Weller Michael, Thon Niklas, Weller Jonathan

Abstract excerpt

BACKGROUND: Survival times of patients with IDH-mutant gliomas are variable and can extend to decades. Many studies provide progression-free rather than overall survival times and prognostic factors remain ill-defined. Here we explored characteristics of short- and long-term survivors within a cohort of patients with extended follow-up. METHODS: This single-center, case-control study included 86 patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Prognosis
Share to Astrocytoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Brain Neoplasms

Share to Follow-Up Studies

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Oligodendroglioma

Share to Survival Rate

Source

Open in PubMed Open full text

Identifiers

PMID: 39316316
DOI: 10.1007/s11060-024-04826-9
PMCID: PMC11614945

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Determinants of long-term survival in patients with IDH-mutant gliomas.PMID 39316316Read ↗

Clinical features, MRI, molecular alternations, and prognosis of astrocytoma based on WHO 2021 classification of central nervous system tumors: A single-center retrospective study.Semantic proximity Read ↗

Differences in the Prognostic Role of Age, Extent of Resection, and Tumor Grade between Astrocytoma IDHmt and Oligodendroglioma: A Single-Center Cohort Study.Semantic proximity Read ↗

A comprehensive clinical, molecular, radiological, and surgical analysis for predicting prognosis in isocitrate dehydrogenase-mutant astrocytoma patients.Semantic proximity Read ↗

Clinical, molecular, and radiological predictors of prognosis in newly diagnosed astrocytoma, IDH-mutant, WHO grade 4.Semantic proximity Read ↗

Incidence and Survival of IDH-Wildtype Glioblastoma and IDH-Mutant Astrocytoma by Treatment and Sex: A Regional Study in Spain (2011-2021).Semantic proximity Read ↗

A multi-center, clinical analysis of IDH-mutant gliomas, WHO Grade 4: implications for prognosis and clinical trial design.Semantic proximity Read ↗

A comparative analysis of IDH-mutant glioma in pediatric, young adult, and older adult patients.Semantic proximity Read ↗

Unlocking new horizons: advances in treating IDH-mutant, 1p/19q-codeleted oligodendrogliomasSemantic proximity Read ↗

Low-grade IDH -mutant gliomas: from standard post-surgical treatments to novel IDH inhibitorsSemantic proximity Read ↗

Treatment and outcomes of IDH1-mutant gliomas in elderly patients.Semantic proximity Read ↗

Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma CohortsSemantic proximity Read ↗

Do Long-Term Survivor Primary Glioblastoma Patients Harbor IDH1 Mutations?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.